Weersma R K, van Dullemen H M, van der Steege G, Nolte I M, Kleibeuker J H, Dijkstra G
Department of Gastroenterology and Hepatology, Section Medical Biology, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands.
Aliment Pharmacol Ther. 2007 Dec;26 Suppl 2:57-65. doi: 10.1111/j.1365-2036.2007.03476.x.
Inflammatory bowel disease (IBD) comprising ulcerative colitis (UC) and Crohn's disease (CD) is multigenic disorder. Tremendous progress has been achieved in unravelling the genetic background of IBD. It has led to the discovery of mutations in NOD2 associated with ileal CD and numerous other genes have been found to be associated with IBD susceptibility.
A review of the literature on the genetic background of IBD was performed.
It is only partially understood how mutations in NOD2 lead to CD. Mouse models, in vitro data and studies in humans offer conflicting data as regards whether there is a loss or gain of function of NOD2 in CD. Several additional genes have been identified of which only a few are currently being recognized as potential disease causing or disease modifying genes. Promising candidate genes include TLR4, MDR1, NOD1 (CARD4), DLG5 as well as the IBD5 locus including SLC22A4/5.
Although genetic research has not yet led to a better prediction of the disease course or patient selection for medical therapy, remarkable progress has been made in the understanding of the pathogenesis of IBD. For future genetic research, accurate phenotyping of patients is very important and large population-based cohorts are needed. Eventually, genetic research may be able to classify different disease phenotypes on a more detailed molecular basis and may provide important contributions in the development of new therapeutic approaches.
炎症性肠病(IBD)包括溃疡性结肠炎(UC)和克罗恩病(CD),是一种多基因疾病。在揭示IBD的遗传背景方面已取得了巨大进展。这导致发现了与回肠CD相关的NOD2突变,并且还发现许多其他基因与IBD易感性有关。
对有关IBD遗传背景的文献进行了综述。
目前仅部分了解NOD2突变如何导致CD。关于CD中NOD2是功能丧失还是功能获得,小鼠模型、体外数据和人体研究提供了相互矛盾的数据。已鉴定出几个其他基因,其中目前只有少数被认为是潜在的致病或疾病修饰基因。有前景的候选基因包括TLR4、MDR1、NOD1(CARD4)、DLG5以及包括SLC22A4/5的IBD5位点。
尽管基因研究尚未能更好地预测疾病进程或为药物治疗选择患者,但在理解IBD的发病机制方面已取得了显著进展。对于未来的基因研究,准确对患者进行表型分型非常重要,并且需要基于大人群的队列研究。最终,基因研究或许能够在更详细的分子基础上对不同的疾病表型进行分类,并可能为新治疗方法的开发做出重要贡献。